社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Tamashii
IP属地:未知
+关注
帖子 · 154
帖子 · 154
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Tamashii
Tamashii
·
2022-01-12
Moderna and nova!
3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>
These three COVID-19 stocks could rake in a tremendous amount of cash this year.
3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>
看
3,262
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-11
Should i buy more?
Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股价能否在2022年收回3万亿美元并蓬勃发展?</blockquote>
A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready
Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股价能否在2022年收回3万亿美元并蓬勃发展?</blockquote>
看
2,468
回复
1
点赞
3
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-09
Technology!
非常抱歉,此主贴已删除
看
2,546
回复
1
点赞
3
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-06
Buy buy!
Grab Stock Slid over 5% in Morning Trading<blockquote>Grab股价早盘下跌超过5%</blockquote>
Grab stock slid over 5% in morning trading.
Grab Stock Slid over 5% in Morning Trading<blockquote>Grab股价早盘下跌超过5%</blockquote>
看
2,107
回复
评论
点赞
2
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-05
Good luck
Stock Futures Waver Ahead of Fed Minutes<blockquote>美联储会议纪要公布前股指波动</blockquote>
U.S. stock futures wobbled as investors awaited minutes from the Federal Reserve’s recent policy mee
Stock Futures Waver Ahead of Fed Minutes<blockquote>美联储会议纪要公布前股指波动</blockquote>
看
2,000
回复
评论
点赞
3
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-04
Gogogo
非常抱歉,此主贴已删除
看
3,095
回复
评论
点赞
2
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-03
Tesla again!
These are the top 3 stocks to watch in 2022: Analyst<blockquote>分析师:这些是2022年最值得关注的3只股票</blockquote>
Investors should keep an eye out for casino and real estate stocks next year, according to Gerber Ka
These are the top 3 stocks to watch in 2022: Analyst<blockquote>分析师:这些是2022年最值得关注的3只股票</blockquote>
看
2,764
回复
评论
点赞
3
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-02
Nice
非常抱歉,此主贴已删除
看
2,318
回复
评论
点赞
2
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2022-01-01
Happy safe new year!
非常抱歉,此主贴已删除
看
3,142
回复
评论
点赞
1
编组 21备份 2
分享
举报
Tamashii
Tamashii
·
2021-12-30
Good luck!
Singapore Stock Market May Fade On Thursday<blockquote>新加坡股市周四可能会褪色</blockquote>
The Singapore stock market has tracked higher in two straight sessions, gathering almost 35 points o
Singapore Stock Market May Fade On Thursday<blockquote>新加坡股市周四可能会褪色</blockquote>
看
2,349
回复
评论
点赞
1
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4087109479010510","uuid":"4087109479010510","gmtCreate":1624006705496,"gmtModify":1624006705496,"name":"Tamashii","pinyin":"tamashii","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":20,"headSize":1,"tweetSize":154,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":694256503,"gmtCreate":1642001753541,"gmtModify":1642001753772,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Moderna and nova!","listText":"Moderna and nova!","text":"Moderna and nova!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694256503","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://www.laohu8.com/m/news/1134509683?lang=zh_CN&edition=full","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<p><html><head></head><body>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>这是新的一年,新冠肺炎仍然和我们在一起。去年,我们看到医疗保健领域多种新冠疫苗和治疗方法获得了紧急使用授权。制药公司将在2022年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>(纽约证券交易所股票代码:PFE)是一家价值3100亿美元的大型公司,预计其新冠疫苗和抗病毒药物的销售额将不会是10亿或100亿美元,而是超过500亿美元。斗志昂扬<b>Novavax</b>(纳斯达克:NVAX)终于在全球范围内推出了新冠疫苗。它将获得多少亿?我们有一个黑马候选人<b>维尔生物技术</b>(纳斯达克:维尔)。对于这家小型生物技术公司来说,它的一种药物很容易成为价值10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源:盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的避风港</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·巴德威尔(辉瑞):</b>辉瑞是新冠肺炎制药产品无可争议的冠军。仅在2022年,华尔街预计这家制药巨头的新型冠状病毒疫苗Comirnaty和口服抗病毒药物Paxlovid的销售额就将达到550亿美元。</blockquote></p><p>What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是,分析师开始接受Paxlovid可能在当前十年内成为该公司可持续收入来源的想法。当该药物上个月首次被美国食品和药物管理局根据紧急使用授权途径允许上市时,华尔街认为从商业角度来看,Paxlovid可能会在一年左右的时间内达到顶峰,然后随着疫情从视野中消失,销售额急剧下降。</blockquote></p><p>But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次获得批准还不到三周,令人痛苦的是,很明显,Paxlovid可能需要作为未来几年COVID-19最坏结果的故障保险。毕竟,高传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着,辉瑞应该是少数几家在新冠肺炎拥有可观、长期收入来源的大型制药商之一。反过来,在可预见的未来,辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及雄心勃勃的业务发展计划。</blockquote></p><p>So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此,如果您正在寻找一只能够抵御极高通胀和利率上升双重阻力的股票,辉瑞可能值得一试。</blockquote></p><p><b>Revenue forecasts for Novavax: $2 billion to $8 billion</b></p><p><blockquote><b>Novavax的收入预测:20亿至80亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔(Novavax):</b>Novavax今年正处于伟大的边缘。该公司的股价跌至每股125美元。这就是它在2021年开始的地方,所以去年该股几乎遭受了洗盘。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在2月份,当Novavax报告其新冠疫苗的积极3期数据时,股价就飙升至300美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人说它的疫苗是同类产品中最好的,但扩大约20亿剂疫苗的合同生产说起来容易做起来难。这些现实导致该股较高点下跌约60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此,Novavax的收入已经达到了10亿美元大关,因此由于所有的预订,其疫苗甚至在获得批准之前就已经一鸣惊人。现在,全球各地的授权纷至沓来,Novavax很有可能在2022年运送大量疫苗。该公司已经实现了每月1亿剂的生产能力,即一年12亿剂。在第三季度收益看涨期权上,管理层预测到第四季度末将达到每月1.5亿剂(或每年18亿剂)的生产能力。该公司预计将继续扩大规模,并预测2022年将分发20亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗,价格为16美元(曲速行动支付了16亿美元预购了1亿剂疫苗),我们粗略计算出收入为320亿美元。当然,Novavax将以较低的速度向发展中国家分发大量疫苗。尽管该公司对其价格保持沉默,但丹麦早在8月份就表示,根据欧盟(EU)协议,它为每剂疫苗支付了近21美元。欧盟已经订购了2亿剂,因此仅在欧洲的销售额就超过40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师非常保守,对Novavax 2022年的预测在20亿至80亿美元之间。(该公司的市值为90亿美元。)虽然一路上可能会出现一些问题,但Novavax肯定会在2022年从其COVID-19疫苗中赚取数十亿美元。如果该公司确实像其所说的那样交付20亿剂疫苗,该股可能会有大幅上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场全靠自己</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma(Vir Biotechnology):</b>奥密克戎变种目前猖獗,这一次,我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来公司</b>(bamlanivimab加etesevimab)以及来自<b>罗氏</b>和<b>再生</b>被认为对当前变体的活性显著降低。这样就只剩下一种对奥密克戎有效的输液了--<b>葛兰素史克</b>以及Vir Biotechnology的sotrovimab。这种单克隆抗体先前证明,在轻度至中度新冠肺炎和进展为重度疾病的高风险成人中,住院和死亡风险降低了79%。它是目前唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为唯一的单克隆抗体将有其特权。2021年前9个月,REGEN-COV带来了35亿美元的产品净销售额,而礼来公司的抗体组合带来了11.7亿美元。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院挤满了病人,任何有助于缓解系统压力的东西都可能受到高度追捧。</blockquote></p><p>And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的Paxlovid将极大地有利于减轻医疗保健系统的COVID-19负担,但这种口服药物具有显着且复杂的药物相互作用潜力。事实上,它的相互作用列表读起来就像是常用处方药的名人录。这包括流行的血液稀释剂,如波立维和Xarelto,常见的止痛药,如曲马多和羟考酮,抗焦虑药,如Klonopin和Xanax,以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明,表达了对Paxlovid可能的药物相互作用的担忧,这为sotrovimab继续广泛使用留下了充足的空间。根据与GSK的协议,Vir获得了sotrovimab销售额的72.5%,这家价值44亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022<blockquote>2022年将赚取数十亿美元的3只COVID股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2022-01-08 11:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>这是新的一年,新冠肺炎仍然和我们在一起。去年,我们看到医疗保健领域多种新冠疫苗和治疗方法获得了紧急使用授权。制药公司将在2022年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>(纽约证券交易所股票代码:PFE)是一家价值3100亿美元的大型公司,预计其新冠疫苗和抗病毒药物的销售额将不会是10亿或100亿美元,而是超过500亿美元。斗志昂扬<b>Novavax</b>(纳斯达克:NVAX)终于在全球范围内推出了新冠疫苗。它将获得多少亿?我们有一个黑马候选人<b>维尔生物技术</b>(纳斯达克:维尔)。对于这家小型生物技术公司来说,它的一种药物很容易成为价值10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源:盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的避风港</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·巴德威尔(辉瑞):</b>辉瑞是新冠肺炎制药产品无可争议的冠军。仅在2022年,华尔街预计这家制药巨头的新型冠状病毒疫苗Comirnaty和口服抗病毒药物Paxlovid的销售额就将达到550亿美元。</blockquote></p><p>What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是,分析师开始接受Paxlovid可能在当前十年内成为该公司可持续收入来源的想法。当该药物上个月首次被美国食品和药物管理局根据紧急使用授权途径允许上市时,华尔街认为从商业角度来看,Paxlovid可能会在一年左右的时间内达到顶峰,然后随着疫情从视野中消失,销售额急剧下降。</blockquote></p><p>But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次获得批准还不到三周,令人痛苦的是,很明显,Paxlovid可能需要作为未来几年COVID-19最坏结果的故障保险。毕竟,高传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着,辉瑞应该是少数几家在新冠肺炎拥有可观、长期收入来源的大型制药商之一。反过来,在可预见的未来,辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及雄心勃勃的业务发展计划。</blockquote></p><p>So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此,如果您正在寻找一只能够抵御极高通胀和利率上升双重阻力的股票,辉瑞可能值得一试。</blockquote></p><p><b>Revenue forecasts for Novavax: $2 billion to $8 billion</b></p><p><blockquote><b>Novavax的收入预测:20亿至80亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔(Novavax):</b>Novavax今年正处于伟大的边缘。该公司的股价跌至每股125美元。这就是它在2021年开始的地方,所以去年该股几乎遭受了洗盘。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在2月份,当Novavax报告其新冠疫苗的积极3期数据时,股价就飙升至300美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人说它的疫苗是同类产品中最好的,但扩大约20亿剂疫苗的合同生产说起来容易做起来难。这些现实导致该股较高点下跌约60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此,Novavax的收入已经达到了10亿美元大关,因此由于所有的预订,其疫苗甚至在获得批准之前就已经一鸣惊人。现在,全球各地的授权纷至沓来,Novavax很有可能在2022年运送大量疫苗。该公司已经实现了每月1亿剂的生产能力,即一年12亿剂。在第三季度收益看涨期权上,管理层预测到第四季度末将达到每月1.5亿剂(或每年18亿剂)的生产能力。该公司预计将继续扩大规模,并预测2022年将分发20亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗,价格为16美元(曲速行动支付了16亿美元预购了1亿剂疫苗),我们粗略计算出收入为320亿美元。当然,Novavax将以较低的速度向发展中国家分发大量疫苗。尽管该公司对其价格保持沉默,但丹麦早在8月份就表示,根据欧盟(EU)协议,它为每剂疫苗支付了近21美元。欧盟已经订购了2亿剂,因此仅在欧洲的销售额就超过40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师非常保守,对Novavax 2022年的预测在20亿至80亿美元之间。(该公司的市值为90亿美元。)虽然一路上可能会出现一些问题,但Novavax肯定会在2022年从其COVID-19疫苗中赚取数十亿美元。如果该公司确实像其所说的那样交付20亿剂疫苗,该股可能会有大幅上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场全靠自己</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma(Vir Biotechnology):</b>奥密克戎变种目前猖獗,这一次,我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来公司</b>(bamlanivimab加etesevimab)以及来自<b>罗氏</b>和<b>再生</b>被认为对当前变体的活性显著降低。这样就只剩下一种对奥密克戎有效的输液了--<b>葛兰素史克</b>以及Vir Biotechnology的sotrovimab。这种单克隆抗体先前证明,在轻度至中度新冠肺炎和进展为重度疾病的高风险成人中,住院和死亡风险降低了79%。它是目前唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为唯一的单克隆抗体将有其特权。2021年前9个月,REGEN-COV带来了35亿美元的产品净销售额,而礼来公司的抗体组合带来了11.7亿美元。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院挤满了病人,任何有助于缓解系统压力的东西都可能受到高度追捧。</blockquote></p><p>And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的Paxlovid将极大地有利于减轻医疗保健系统的COVID-19负担,但这种口服药物具有显着且复杂的药物相互作用潜力。事实上,它的相互作用列表读起来就像是常用处方药的名人录。这包括流行的血液稀释剂,如波立维和Xarelto,常见的止痛药,如曲马多和羟考酮,抗焦虑药,如Klonopin和Xanax,以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明,表达了对Paxlovid可能的药物相互作用的担忧,这为sotrovimab继续广泛使用留下了充足的空间。根据与GSK的协议,Vir获得了sotrovimab销售额的72.5%,这家价值44亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Motley Fool</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax: $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"VIR":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694841358,"gmtCreate":1641916024274,"gmtModify":1641916059042,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Should i buy more?","listText":"Should i buy more?","text":"Should i buy more?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694841358","repostId":"1198290127","repostType":4,"repost":{"id":"1198290127","kind":"news","pubTimestamp":1641702682,"share":"https://www.laohu8.com/m/news/1198290127?lang=zh_CN&edition=full","pubTime":"2022-01-09 12:31","market":"us","language":"en","title":"Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股价能否在2022年收回3万亿美元并蓬勃发展?</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198290127","media":"TheStreet","summary":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready","content":"<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止,3万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快恢复里程碑并在2022年走高?</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近,苹果股票的市值曾一度接近3万亿美元,但很快跌破2.9万亿美元——因为大盘对货币紧缩的反应现在应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股价能否最终在2022年找到北上之路,并满足华尔街众多多头的预期?或者,在利率上升和通胀挥之不去的一年里,看跌情绪会占上风吗?</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1:加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>苹果公司:牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在11月底至12月初期间恶性攀升,许多华尔街专家纷纷支持“AAPL$3T”。例如,至少自去年第三季度我们的谈话以来,Wedbush的Dan Ives一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在11月份将目标价上调至每股200美元,而摩根大通研究团队预计苹果股票的市值将在未来12个月内达到3.5万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup的吉恩·蒙斯特(Gene Munster)认为,他之前的目标价很快就过时了,现在每股250美元似乎更合理。他认为,元宇宙的多年机会将在新的一年里获得投资者的赞赏,这应该会重新点燃该股在2021年最后几周失去的动力。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>苹果公司:熊市案例</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管存在上述乐观预期,主要受到公司特定因素的支持,但市场在进入2022年时仍保持警惕。眼下的恶魔似乎是美联储对接近充分就业和粘性通胀的预期反应,这应该会导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然AAPL不是特斯拉或Rivian,但该股近30倍的预期市盈率和仅温和的盈利增长预期可能会拖累2022年的股价,因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的优秀股票。在以卓越运营为驱动力的首席执行官(和前首席运营官)的领导下,该公司似乎得到了很好的管理。更好的是,对苹果产品和服务的需求以及消费者对该品牌的赞赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说,2022年前几周或几个月的设置对我来说看起来很有挑战性。苹果股价在2020年无情攀升,去年再次攀升。得益于大流行推动的科技设备需求激增以及系统中充裕的流动性,AAPL在2019年至2021年间创下了有史以来最好的三年回报率之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够而且很可能支持公司未来许多年的财务业绩,但我认为苹果公司的股票早就应该喘口气了。虽然股价可能会回升至3万亿美元以上,并最终进一步走高,但我对这种反弹会在不久的将来发生不太有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股价能否在2022年收回3万亿美元并蓬勃发展?</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股价能否在2022年收回3万亿美元并蓬勃发展?</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2022-01-09 12:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止,3万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快恢复里程碑并在2022年走高?</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近,苹果股票的市值曾一度接近3万亿美元,但很快跌破2.9万亿美元——因为大盘对货币紧缩的反应现在应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股价能否最终在2022年找到北上之路,并满足华尔街众多多头的预期?或者,在利率上升和通胀挥之不去的一年里,看跌情绪会占上风吗?</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1:加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>苹果公司:牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在11月底至12月初期间恶性攀升,许多华尔街专家纷纷支持“AAPL$3T”。例如,至少自去年第三季度我们的谈话以来,Wedbush的Dan Ives一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在11月份将目标价上调至每股200美元,而摩根大通研究团队预计苹果股票的市值将在未来12个月内达到3.5万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup的吉恩·蒙斯特(Gene Munster)认为,他之前的目标价很快就过时了,现在每股250美元似乎更合理。他认为,元宇宙的多年机会将在新的一年里获得投资者的赞赏,这应该会重新点燃该股在2021年最后几周失去的动力。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>苹果公司:熊市案例</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管存在上述乐观预期,主要受到公司特定因素的支持,但市场在进入2022年时仍保持警惕。眼下的恶魔似乎是美联储对接近充分就业和粘性通胀的预期反应,这应该会导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然AAPL不是特斯拉或Rivian,但该股近30倍的预期市盈率和仅温和的盈利增长预期可能会拖累2022年的股价,因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的优秀股票。在以卓越运营为驱动力的首席执行官(和前首席运营官)的领导下,该公司似乎得到了很好的管理。更好的是,对苹果产品和服务的需求以及消费者对该品牌的赞赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说,2022年前几周或几个月的设置对我来说看起来很有挑战性。苹果股价在2020年无情攀升,去年再次攀升。得益于大流行推动的科技设备需求激增以及系统中充裕的流动性,AAPL在2019年至2021年间创下了有史以来最好的三年回报率之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够而且很可能支持公司未来许多年的财务业绩,但我认为苹果公司的股票早就应该喘口气了。虽然股价可能会回升至3万亿美元以上,并最终进一步走高,但我对这种反弹会在不久的将来发生不太有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022\">TheStreet</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198290127","content_text":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?Figure 1: Apple Park in Cupertino, CA.AAPL: the bull caseAs Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.AAPL: the bear caseDespite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.The Apple Maven’s takeI continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694089396,"gmtCreate":1641698848907,"gmtModify":1641698849225,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Technology!","listText":"Technology!","text":"Technology!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694089396","repostId":"2201214004","repostType":4,"isVote":1,"tweetType":1,"viewCount":2546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695271037,"gmtCreate":1641484457431,"gmtModify":1641484457645,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Buy buy!","listText":"Buy buy!","text":"Buy buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695271037","repostId":"1154834453","repostType":4,"repost":{"id":"1154834453","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641481305,"share":"https://www.laohu8.com/m/news/1154834453?lang=zh_CN&edition=full","pubTime":"2022-01-06 23:01","market":"us","language":"en","title":"Grab Stock Slid over 5% in Morning Trading<blockquote>Grab股价早盘下跌超过5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1154834453","media":"Tiger Newspress","summary":"Grab stock slid over 5% in morning trading.","content":"<p><html><head></head><body>Grab stock slid over 5% in morning trading.<img src=\"https://static.tigerbbs.com/98069cd31091bf55c09da39c6266d483\" tg-width=\"1115\" tg-height=\"752\" width=\"100%\" height=\"auto\"/></p><p><blockquote><html><head></head><body>Grab股价早盘下跌超过5%。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab Stock Slid over 5% in Morning Trading<blockquote>Grab股价早盘下跌超过5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab Stock Slid over 5% in Morning Trading<blockquote>Grab股价早盘下跌超过5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2022-01-06 23:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Grab stock slid over 5% in morning trading.<img src=\"https://static.tigerbbs.com/98069cd31091bf55c09da39c6266d483\" tg-width=\"1115\" tg-height=\"752\" width=\"100%\" height=\"auto\"/></p><p><blockquote><html><head></head><body>Grab股价早盘下跌超过5%。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154834453","content_text":"Grab stock slid over 5% in morning trading.","news_type":1,"symbols_score_info":{"GRAB":0.9}},"isVote":1,"tweetType":1,"viewCount":2107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695895743,"gmtCreate":1641392188589,"gmtModify":1641392188837,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Good luck","listText":"Good luck","text":"Good luck","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695895743","repostId":"1126343636","repostType":4,"repost":{"id":"1126343636","kind":"news","pubTimestamp":1641378781,"share":"https://www.laohu8.com/m/news/1126343636?lang=zh_CN&edition=full","pubTime":"2022-01-05 18:33","market":"fut","language":"en","title":"Stock Futures Waver Ahead of Fed Minutes<blockquote>美联储会议纪要公布前股指波动</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1126343636","media":"WSJ","summary":"U.S. stock futures wobbled as investors awaited minutes from the Federal Reserve’s recent policy mee","content":"<p><html><head></head><body>U.S. stock futures wobbled as investors awaited minutes from the Federal Reserve’s recent policy meeting in the hope of gleaning fresh clues about plans to wean markets off pandemic-era stimulus measures.</p><p><blockquote><html><head></head><body>由于投资者等待美联储最近的政策会议纪要,希望收集有关让市场摆脱大流行时期刺激措施的计划的新线索,美国股指期货出现波动。</body></html></blockquote></p><p>Futures tied to the S&P 500 flicked between small gains and losses Wednesday, a day after the broad index pulled from a record high as technology firms fell.Futures for the tech-heavy Nasdaq-100 fell 0.3% Wednesday, while blue-chip Dow Jones Industrial Average futures were unchanged.</p><p><blockquote>周三,与标普500相关的期货在小幅涨跌之间波动,此前一天,随着科技公司下跌,该指数从历史高点回落。以科技股为主的纳斯达克100指数期货周三下跌0.3%,而蓝筹股道琼斯工业平均指数期货没有变化。</blockquote></p><p>Markets have largely begun 2022 on a strong footing, lifted by easing concerns about the Omicron Covid-19 variant. Signs that the variant is less likely to cause severe disease means investors are betting it won’t derail strong growth for the economy and corporate earnings.</p><p><blockquote>由于对奥密克戎Covid-19变种的担忧缓解,市场在2022年伊始基本处于强劲的基础上。有迹象表明,该变种不太可能导致严重疾病,这意味着投资者押注它不会破坏经济和企业盈利的强劲增长。</blockquote></p><p>“We essentially have been seeing earlier signs that Omicron is probably not as problematic as we initially feared,” said Hani Redha, a portfolio manager at PineBridge Investments. “Markets are very good at sniffing these things out, at identifying what things we should look through.”</p><p><blockquote>PineBridge Investments投资组合经理哈尼·雷德哈(Hani Redha)表示:“我们基本上已经看到早期迹象表明,奥密克戎可能并不像我们最初担心的那样存在问题。”“市场非常擅长嗅出这些东西,确定我们应该关注哪些东西。”</blockquote></p><p>Investors’ focus is shifting away from the new variant to moves by global central banks to tighten monetary policy as economies recover further.</p><p><blockquote>随着经济进一步复苏,投资者的关注点正从新变种转向全球央行收紧货币政策的举措。</blockquote></p><p>“We expect growth to deflate as we go through the year. That will happen naturally. As the monetary, fiscal support fades, markets will have to stand on their own two feet,” said Mr. Redha. “It’s not a disaster but it is a headwind at the same time that central banks are on the move.”</p><p><blockquote>雷德哈表示:“我们预计,随着今年的过去,经济增长将出现萎缩。这将自然而然地发生。随着货币和财政支持的消退,市场将不得不自立。”“这不是一场灾难,但在央行采取行动的同时,这也是一个阻力。”</blockquote></p><p>Minutes from the Fed’s December meeting are set to be released at 2 p.m. ET. Fed officials said in that meeting they would speed up the pace at which stimulus measures are withdrawn, and issued projections for three interest rate rises in 2022.</p><p><blockquote>美联储12月会议纪要将于美国东部时间下午2点公布。美联储官员在那次会议上表示,他们将加快退出刺激措施的步伐,并发布了2022年三次加息的预测。</blockquote></p><p>The pivot from the Fed has pushed bond yields higher, which in turn has weighed on technology firms whose future earnings become less attractive when compared with bonds with rising yields.</p><p><blockquote>美联储的转向推高了债券收益率,这反过来又给科技公司带来了压力,与收益率上升的债券相比,这些公司的未来盈利变得不那么有吸引力。</blockquote></p><p>The yield on the benchmark 10-Year U.S. Treasury note fell to 1.650% Wednesday from 1.666% Tuesday, but remained close to a six-week high. Bond yields rise as prices fall.</p><p><blockquote>基准10年期美国国债收益率周三从周二的1.666%降至1.650%,但仍接近六周高点。随着价格下跌,债券收益率上升。</blockquote></p><p>Data on the U.S. service sector, as well as a private sector gauge of the labor market, are due at 9:45 a.m. and 8:15 a.m., respectively.</p><p><blockquote>美国服务业数据以及私营部门劳动力市场指标分别于上午9:45和8:15公布。</blockquote></p><p>In commodity markets, Brent crude, the international oil benchmark, edged down 0.5% to $79.63 a barrel. On Tuesday, oil prices surged after the Organization of the Petroleum Exporting Countries and a coalition of Russia-led group of oil producers agreed to continue pumping more crude.</p><p><blockquote>大宗商品市场方面,国际石油基准布伦特原油小幅下跌0.5%,至每桶79.63美元。周二,在石油输出国组织和俄罗斯领导的产油国联盟同意继续生产更多原油后,油价飙升。</blockquote></p><p>Overseas, the Stoxx Europe 600 was largely unchanged in early trading. In Asia, stock markets were mostly lower. In Hong Kong, the Hang Seng Index fell 1.6% while in mainland China, the Shanghai Composite Index dropped 1%. In Japan, the Nikkei 225 edged up 0.1%.</p><p><blockquote>海外方面,欧洲斯托克600指数早盘基本持平。在亚洲,股市大多走低。在香港,恒生指数下跌1.6%,而在mainland China,上证综合指数下跌1%。在日本,日经225指数小幅上涨0.1%。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Futures Waver Ahead of Fed Minutes<blockquote>美联储会议纪要公布前股指波动</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Futures Waver Ahead of Fed Minutes<blockquote>美联储会议纪要公布前股指波动</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2022-01-05 18:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>U.S. stock futures wobbled as investors awaited minutes from the Federal Reserve’s recent policy meeting in the hope of gleaning fresh clues about plans to wean markets off pandemic-era stimulus measures.</p><p><blockquote><html><head></head><body>由于投资者等待美联储最近的政策会议纪要,希望收集有关让市场摆脱大流行时期刺激措施的计划的新线索,美国股指期货出现波动。</body></html></blockquote></p><p>Futures tied to the S&P 500 flicked between small gains and losses Wednesday, a day after the broad index pulled from a record high as technology firms fell.Futures for the tech-heavy Nasdaq-100 fell 0.3% Wednesday, while blue-chip Dow Jones Industrial Average futures were unchanged.</p><p><blockquote>周三,与标普500相关的期货在小幅涨跌之间波动,此前一天,随着科技公司下跌,该指数从历史高点回落。以科技股为主的纳斯达克100指数期货周三下跌0.3%,而蓝筹股道琼斯工业平均指数期货没有变化。</blockquote></p><p>Markets have largely begun 2022 on a strong footing, lifted by easing concerns about the Omicron Covid-19 variant. Signs that the variant is less likely to cause severe disease means investors are betting it won’t derail strong growth for the economy and corporate earnings.</p><p><blockquote>由于对奥密克戎Covid-19变种的担忧缓解,市场在2022年伊始基本处于强劲的基础上。有迹象表明,该变种不太可能导致严重疾病,这意味着投资者押注它不会破坏经济和企业盈利的强劲增长。</blockquote></p><p>“We essentially have been seeing earlier signs that Omicron is probably not as problematic as we initially feared,” said Hani Redha, a portfolio manager at PineBridge Investments. “Markets are very good at sniffing these things out, at identifying what things we should look through.”</p><p><blockquote>PineBridge Investments投资组合经理哈尼·雷德哈(Hani Redha)表示:“我们基本上已经看到早期迹象表明,奥密克戎可能并不像我们最初担心的那样存在问题。”“市场非常擅长嗅出这些东西,确定我们应该关注哪些东西。”</blockquote></p><p>Investors’ focus is shifting away from the new variant to moves by global central banks to tighten monetary policy as economies recover further.</p><p><blockquote>随着经济进一步复苏,投资者的关注点正从新变种转向全球央行收紧货币政策的举措。</blockquote></p><p>“We expect growth to deflate as we go through the year. That will happen naturally. As the monetary, fiscal support fades, markets will have to stand on their own two feet,” said Mr. Redha. “It’s not a disaster but it is a headwind at the same time that central banks are on the move.”</p><p><blockquote>雷德哈表示:“我们预计,随着今年的过去,经济增长将出现萎缩。这将自然而然地发生。随着货币和财政支持的消退,市场将不得不自立。”“这不是一场灾难,但在央行采取行动的同时,这也是一个阻力。”</blockquote></p><p>Minutes from the Fed’s December meeting are set to be released at 2 p.m. ET. Fed officials said in that meeting they would speed up the pace at which stimulus measures are withdrawn, and issued projections for three interest rate rises in 2022.</p><p><blockquote>美联储12月会议纪要将于美国东部时间下午2点公布。美联储官员在那次会议上表示,他们将加快退出刺激措施的步伐,并发布了2022年三次加息的预测。</blockquote></p><p>The pivot from the Fed has pushed bond yields higher, which in turn has weighed on technology firms whose future earnings become less attractive when compared with bonds with rising yields.</p><p><blockquote>美联储的转向推高了债券收益率,这反过来又给科技公司带来了压力,与收益率上升的债券相比,这些公司的未来盈利变得不那么有吸引力。</blockquote></p><p>The yield on the benchmark 10-Year U.S. Treasury note fell to 1.650% Wednesday from 1.666% Tuesday, but remained close to a six-week high. Bond yields rise as prices fall.</p><p><blockquote>基准10年期美国国债收益率周三从周二的1.666%降至1.650%,但仍接近六周高点。随着价格下跌,债券收益率上升。</blockquote></p><p>Data on the U.S. service sector, as well as a private sector gauge of the labor market, are due at 9:45 a.m. and 8:15 a.m., respectively.</p><p><blockquote>美国服务业数据以及私营部门劳动力市场指标分别于上午9:45和8:15公布。</blockquote></p><p>In commodity markets, Brent crude, the international oil benchmark, edged down 0.5% to $79.63 a barrel. On Tuesday, oil prices surged after the Organization of the Petroleum Exporting Countries and a coalition of Russia-led group of oil producers agreed to continue pumping more crude.</p><p><blockquote>大宗商品市场方面,国际石油基准布伦特原油小幅下跌0.5%,至每桶79.63美元。周二,在石油输出国组织和俄罗斯领导的产油国联盟同意继续生产更多原油后,油价飙升。</blockquote></p><p>Overseas, the Stoxx Europe 600 was largely unchanged in early trading. In Asia, stock markets were mostly lower. In Hong Kong, the Hang Seng Index fell 1.6% while in mainland China, the Shanghai Composite Index dropped 1%. In Japan, the Nikkei 225 edged up 0.1%.</p><p><blockquote>海外方面,欧洲斯托克600指数早盘基本持平。在亚洲,股市大多走低。在香港,恒生指数下跌1.6%,而在mainland China,上证综合指数下跌1%。在日本,日经225指数小幅上涨0.1%。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.wsj.com/articles/global-stock-markets-dow-update-01-05-2022-11641374345?mod=markets_lead_pos2\">WSJ</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.wsj.com/articles/global-stock-markets-dow-update-01-05-2022-11641374345?mod=markets_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126343636","content_text":"U.S. stock futures wobbled as investors awaited minutes from the Federal Reserve’s recent policy meeting in the hope of gleaning fresh clues about plans to wean markets off pandemic-era stimulus measures.Futures tied to the S&P 500 flicked between small gains and losses Wednesday, a day after the broad index pulled from a record high as technology firms fell.Futures for the tech-heavy Nasdaq-100 fell 0.3% Wednesday, while blue-chip Dow Jones Industrial Average futures were unchanged.Markets have largely begun 2022 on a strong footing, lifted by easing concerns about the Omicron Covid-19 variant. Signs that the variant is less likely to cause severe disease means investors are betting it won’t derail strong growth for the economy and corporate earnings.“We essentially have been seeing earlier signs that Omicron is probably not as problematic as we initially feared,” said Hani Redha, a portfolio manager at PineBridge Investments. “Markets are very good at sniffing these things out, at identifying what things we should look through.”Investors’ focus is shifting away from the new variant to moves by global central banks to tighten monetary policy as economies recover further.“We expect growth to deflate as we go through the year. That will happen naturally. As the monetary, fiscal support fades, markets will have to stand on their own two feet,” said Mr. Redha. “It’s not a disaster but it is a headwind at the same time that central banks are on the move.”Minutes from the Fed’s December meeting are set to be released at 2 p.m. ET. Fed officials said in that meeting they would speed up the pace at which stimulus measures are withdrawn, and issued projections for three interest rate rises in 2022.The pivot from the Fed has pushed bond yields higher, which in turn has weighed on technology firms whose future earnings become less attractive when compared with bonds with rising yields.The yield on the benchmark 10-Year U.S. Treasury note fell to 1.650% Wednesday from 1.666% Tuesday, but remained close to a six-week high. Bond yields rise as prices fall.Data on the U.S. service sector, as well as a private sector gauge of the labor market, are due at 9:45 a.m. and 8:15 a.m., respectively.In commodity markets, Brent crude, the international oil benchmark, edged down 0.5% to $79.63 a barrel. On Tuesday, oil prices surged after the Organization of the Petroleum Exporting Countries and a coalition of Russia-led group of oil producers agreed to continue pumping more crude.Overseas, the Stoxx Europe 600 was largely unchanged in early trading. In Asia, stock markets were mostly lower. In Hong Kong, the Hang Seng Index fell 1.6% while in mainland China, the Shanghai Composite Index dropped 1%. In Japan, the Nikkei 225 edged up 0.1%.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2000,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695927352,"gmtCreate":1641306904391,"gmtModify":1641306904657,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Gogogo","listText":"Gogogo","text":"Gogogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695927352","repostId":"1124443897","repostType":4,"isVote":1,"tweetType":1,"viewCount":3095,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692738715,"gmtCreate":1641212396975,"gmtModify":1641212397180,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Tesla again!","listText":"Tesla again!","text":"Tesla again!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692738715","repostId":"2200443647","repostType":4,"repost":{"id":"2200443647","kind":"news","pubTimestamp":1641175008,"share":"https://www.laohu8.com/m/news/2200443647?lang=zh_CN&edition=full","pubTime":"2022-01-03 09:56","market":"us","language":"en","title":"These are the top 3 stocks to watch in 2022: Analyst<blockquote>分析师:这些是2022年最值得关注的3只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2200443647","media":"Yahoo Finance","summary":"Investors should keep an eye out for casino and real estate stocks next year, according to Gerber Ka","content":"<p><html><head></head><body>Investors should keep an eye out for casino and real estate stocks next year, according to Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.</p><p><blockquote><html><head></head><body>格柏川崎财富与投资管理公司首席执行官罗斯·格柏表示,投资者明年应密切关注赌场和房地产股票。</body></html></blockquote></p><p>MGM (MGM), Lennar (LEN), and Tesla (TSLA) were selected as the top three stocks poised to rise in 2022 in Gerber’s preview. He joined Yahoo Finance Live on Thursday to discuss which stocks should perform best next year.</p><p><blockquote>在Gerber的预览中,米高梅(MGM)、Lennar(LEN)和特斯拉(TSLA)被选为2022年有望上涨的前三只股票。他周四参加了雅虎财经直播,讨论哪些股票明年应该表现最好。</blockquote></p><p>“MGM is a long-term holding of ours and we've been adding to it on the weakness because of Omicron,” Gerber said. “And we absolutely believe this is the endgame for Corona, this winter being sort of one of the tougher winters again. But as each winter rolls on, this will become much more normal and much less disruptive.”</p><p><blockquote>格伯表示:“米高梅是我们的长期持股,由于奥密克戎的疲软,我们一直在增持米高梅。”“我们绝对相信这是新冠疫情的结局,今年冬天再次成为更艰难的冬天之一。但随着每个冬天的到来,这将变得更加正常,破坏性也会小得多。”</blockquote></p><p>MGM Resorts International, a giant in the hospitality and entertainment industry, specializes in casinos, hotels, and resorts. As the global outlook continues to improve and the economy adjusts to the new realities concerning COVID, Gerber noted, the hospitality sector could stand to benefit greatly.</p><p><blockquote>米高梅国际酒店集团是酒店和娱乐业的巨头,专注于赌场、酒店和度假村。格伯指出,随着全球前景持续改善以及经济适应新冠疫情的新现实,酒店业可能会受益匪浅。</blockquote></p><p>The prospect of interest rate hikes in 2022 looms over the economic picture for next year and has dampened some analysts’ expectations for stock market growth. “The probability of a 10% correction in the near term or over the next 12 months is elevated,” Bank of America’s (BAC) U.S. stock and quantitative strategy chief Savita Subramanian told Bloomberg earlier this month.</p><p><blockquote>2022年加息的前景笼罩着明年的经济前景,并抑制了一些分析师对股市增长的预期。美国银行(BAC)美国股票和量化策略主管Savita Subramanian本月早些时候对彭博社表示:“近期或未来12个月内调整10%的可能性很高。”</blockquote></p><p>Gerber, who expressed doubt that all three Fed rate hikes would come in 2022, had a more optimistic disposition.</p><p><blockquote>格伯对美联储三次加息都将在2022年进行表示怀疑,但他的态度更为乐观。</blockquote></p><p>“We actually don't think the Fed will actually hit their three rate hikes next year, we'll see,” he said. “But if it does happen, it won't be till the end of the year, and so housing is a supply and demand imbalance on a massive scale. And home builders like Lennar, especially Lennar, which is a really large, established home builder in multiple regions, are just benefiting from this enormous demand. So every house they're building, the profits just go up every month because prices keep going up.”</p><p><blockquote>“我们实际上认为美联储明年不会真正加息三次,我们拭目以待,”他说。“但如果真的发生,也要到今年年底,因此住房是大规模的供需失衡。像Lennar这样的房屋建筑商,尤其是Lennar,这是一家非常大的、成熟的房屋建筑商在多个地区,正是从这种巨大的需求中受益。因此,他们建造的每栋房子,利润每个月都会增加,因为价格不断上涨。”</blockquote></p><p>Lennar, a Florida-based home construction company, has suffered recently from supply chain disruptions related to the pandemic. However, industry experts expect many of these challenges within the housing market to be overcome next year. Research and Markets reported that the U.S. construction industry is expected to grow by 3.7% in 2022.</p><p><blockquote>Lennar是一家总部位于佛罗里达州的住宅建筑公司,最近遭受了与疫情相关的供应链中断。然而,行业专家预计,房地产市场中的许多挑战将在明年得到克服。Research and Markets报告称,预计2022年美国建筑业将增长3.7%。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8038b8b290f38bd18329917959e39f73\" tg-width=\"6000\" tg-height=\"4000\" width=\"100%\" height=\"auto\"/><span>NEWARK, CALIFORNIA - DECEMBER 15: A worker makes repairs to a home under construction at the Lennar Bridgeway home development on December 15, 2021 in Newark, California. Homebuilder Lennar will report fourth quarter earnings today after the closing bell. (Photo by Justin Sullivan/Getty Images)Justin Sullivan via Getty Images</span></p><p><blockquote><p class=\"t-img-caption\"><span>加利福尼亚州纽瓦克-12月15日:2021年12月15日,加利福尼亚州纽瓦克,一名工人在Lennar Bridgeway home development的一栋在建房屋上进行维修。住宅建筑商Lennar将于今天收盘后公布第四季度收益。(贾斯汀·沙利文/盖蒂图片社摄)贾斯汀·沙利文来自盖蒂图片社</span></p></blockquote></p><p>Throughout most of the year, the housing market has remained hot. Similar to other industries, like electronics, housing has faced supply bottlenecks and labor shortages which have restricted supply in the face of rising demand. The Federal Housing Finance Agency reported that housing prices grew 18.5% through 2021 Q3 compared to a year ago, culminating in the largest annual increase in the agency’s House Price Index.</p><p><blockquote>在这一年的大部分时间里,住房市场一直保持着火热。与电子等其他行业类似,住房面临供应瓶颈和劳动力短缺,在需求不断增长的情况下限制了供应。联邦住房金融局报告称,截至2021年第三季度,房价同比增长18.5%,最终创下该机构房价指数的最大年度涨幅。</blockquote></p><p><img src=\"https://static.tigerbbs.com/125965aa9230614070fe2f36dbe141ba\" tg-width=\"819\" tg-height=\"688\" width=\"100%\" height=\"auto\"/></p><p><blockquote></blockquote></p><p>Tesla was Gerber’s last recommendation, and his number one pick for investors in 2022. He had some bold predictions for the EV maker in his interview with Yahoo Finance Live.</p><p><blockquote>特斯拉是格伯的最后推荐,也是他2022年投资者的首选。他在接受雅虎财经直播采访时对这家电动汽车制造商做出了一些大胆的预测。</blockquote></p><p>“I think over the next decade, Tesla will be the most consequential company in the history of business,” Gerber said. “I think in 12 months, we're going to see amazing breakthroughs in AI and technology. And what Elon has done yet, we don't know, you want to own stock in this future. So with robotics, AI, and the dominance in the EV and climate space, Tesla is the best stock of all time.”</p><p><blockquote>“我认为在未来十年,特斯拉将成为商业史上最重要的公司,”格伯说。“我认为在12个月内,我们将看到人工智能和技术方面的惊人突破。而Elon到目前为止做了什么,我们不知道,你想在未来拥有股票。因此,凭借机器人、人工智能和在电动汽车和气候领域的主导地位,特斯拉是有史以来最好的股票。”</blockquote></p><p>Tesla certainly rewarded bullish investors in 2021. This year, Tesla stock has gained 56%, more than double the S&P 500’s 27% rise.</p><p><blockquote>特斯拉无疑在2021年回报了看涨的投资者。今年,特斯拉股价已上涨56%,是标普500 27%涨幅的两倍多。</blockquote></p><p>Even so, challenges remain. The company recalled nearly half a million of its Model 3 and Model S over safety issues concerning the cars’ rear view cameras and trunk. Industry experts have raised concerns regarding the sustainability of Tesla’s high market share in the EV market, as well as the possible emergence of competitors.</p><p><blockquote>即便如此,挑战依然存在。由于后视摄像头和后备箱存在安全问题,该公司召回了近50万辆Model 3和Model S。行业专家对特斯拉在电动汽车市场的高市场份额的可持续性以及可能出现的竞争对手表示担忧。</blockquote></p><p>Gerber cautioned investors not to be too concerned about the recalls. Recalls are relatively normal for car companies, and Tesla’s main strengths lay outside of their automobile services, anyway, he added.</p><p><blockquote>格柏警告投资者不要过于担心召回事件。他补充说,召回对于汽车公司来说是相对正常的,无论如何,特斯拉的主要优势在于汽车服务之外。</blockquote></p><p></p><p>“Tesla is a better AI technology company than a car company, as we've all learned over the last 10 years,” he said. “They build cars, but they're basically building an iPhone on wheels. And so the entire infrastructure that they've been building around service, for example, has been a big challenge for them. They've innovated some amazing things like mobile service.”</p><p><blockquote>“正如我们在过去10年中都了解到的那样,特斯拉是一家比汽车公司更好的人工智能技术公司,”他说。“他们制造汽车,但他们基本上是在制造一部带轮子的iPhone。因此,例如,他们围绕服务构建的整个基础设施对他们来说是一个巨大的挑战。他们创新了一些令人惊叹的东西,比如移动服务。”</blockquote></p><p>Overall, stocks stayed flat on the final trading day of 2021, giving this year’s Santa Claus Rally a rather muted finish. The S&P 500 reached an intraday high Thursday but fell in the afternoon. This year, the index reached a record high every month, a feat achieved only once before, in 2014.</p><p><blockquote>总体而言,股市在2021年最后一个交易日持平,让今年的圣诞老人反弹收官相当平淡。标普500周四触及盘中高点,但午后下跌。今年,该指数每个月都创下历史新高,此前仅在2014年实现过一次。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the top 3 stocks to watch in 2022: Analyst<blockquote>分析师:这些是2022年最值得关注的3只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the top 3 stocks to watch in 2022: Analyst<blockquote>分析师:这些是2022年最值得关注的3只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2022-01-03 09:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Investors should keep an eye out for casino and real estate stocks next year, according to Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.</p><p><blockquote><html><head></head><body>格柏川崎财富与投资管理公司首席执行官罗斯·格柏表示,投资者明年应密切关注赌场和房地产股票。</body></html></blockquote></p><p>MGM (MGM), Lennar (LEN), and Tesla (TSLA) were selected as the top three stocks poised to rise in 2022 in Gerber’s preview. He joined Yahoo Finance Live on Thursday to discuss which stocks should perform best next year.</p><p><blockquote>在Gerber的预览中,米高梅(MGM)、Lennar(LEN)和特斯拉(TSLA)被选为2022年有望上涨的前三只股票。他周四参加了雅虎财经直播,讨论哪些股票明年应该表现最好。</blockquote></p><p>“MGM is a long-term holding of ours and we've been adding to it on the weakness because of Omicron,” Gerber said. “And we absolutely believe this is the endgame for Corona, this winter being sort of one of the tougher winters again. But as each winter rolls on, this will become much more normal and much less disruptive.”</p><p><blockquote>格伯表示:“米高梅是我们的长期持股,由于奥密克戎的疲软,我们一直在增持米高梅。”“我们绝对相信这是新冠疫情的结局,今年冬天再次成为更艰难的冬天之一。但随着每个冬天的到来,这将变得更加正常,破坏性也会小得多。”</blockquote></p><p>MGM Resorts International, a giant in the hospitality and entertainment industry, specializes in casinos, hotels, and resorts. As the global outlook continues to improve and the economy adjusts to the new realities concerning COVID, Gerber noted, the hospitality sector could stand to benefit greatly.</p><p><blockquote>米高梅国际酒店集团是酒店和娱乐业的巨头,专注于赌场、酒店和度假村。格伯指出,随着全球前景持续改善以及经济适应新冠疫情的新现实,酒店业可能会受益匪浅。</blockquote></p><p>The prospect of interest rate hikes in 2022 looms over the economic picture for next year and has dampened some analysts’ expectations for stock market growth. “The probability of a 10% correction in the near term or over the next 12 months is elevated,” Bank of America’s (BAC) U.S. stock and quantitative strategy chief Savita Subramanian told Bloomberg earlier this month.</p><p><blockquote>2022年加息的前景笼罩着明年的经济前景,并抑制了一些分析师对股市增长的预期。美国银行(BAC)美国股票和量化策略主管Savita Subramanian本月早些时候对彭博社表示:“近期或未来12个月内调整10%的可能性很高。”</blockquote></p><p>Gerber, who expressed doubt that all three Fed rate hikes would come in 2022, had a more optimistic disposition.</p><p><blockquote>格伯对美联储三次加息都将在2022年进行表示怀疑,但他的态度更为乐观。</blockquote></p><p>“We actually don't think the Fed will actually hit their three rate hikes next year, we'll see,” he said. “But if it does happen, it won't be till the end of the year, and so housing is a supply and demand imbalance on a massive scale. And home builders like Lennar, especially Lennar, which is a really large, established home builder in multiple regions, are just benefiting from this enormous demand. So every house they're building, the profits just go up every month because prices keep going up.”</p><p><blockquote>“我们实际上认为美联储明年不会真正加息三次,我们拭目以待,”他说。“但如果真的发生,也要到今年年底,因此住房是大规模的供需失衡。像Lennar这样的房屋建筑商,尤其是Lennar,这是一家非常大的、成熟的房屋建筑商在多个地区,正是从这种巨大的需求中受益。因此,他们建造的每栋房子,利润每个月都会增加,因为价格不断上涨。”</blockquote></p><p>Lennar, a Florida-based home construction company, has suffered recently from supply chain disruptions related to the pandemic. However, industry experts expect many of these challenges within the housing market to be overcome next year. Research and Markets reported that the U.S. construction industry is expected to grow by 3.7% in 2022.</p><p><blockquote>Lennar是一家总部位于佛罗里达州的住宅建筑公司,最近遭受了与疫情相关的供应链中断。然而,行业专家预计,房地产市场中的许多挑战将在明年得到克服。Research and Markets报告称,预计2022年美国建筑业将增长3.7%。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8038b8b290f38bd18329917959e39f73\" tg-width=\"6000\" tg-height=\"4000\" width=\"100%\" height=\"auto\"/><span>NEWARK, CALIFORNIA - DECEMBER 15: A worker makes repairs to a home under construction at the Lennar Bridgeway home development on December 15, 2021 in Newark, California. Homebuilder Lennar will report fourth quarter earnings today after the closing bell. (Photo by Justin Sullivan/Getty Images)Justin Sullivan via Getty Images</span></p><p><blockquote><p class=\"t-img-caption\"><span>加利福尼亚州纽瓦克-12月15日:2021年12月15日,加利福尼亚州纽瓦克,一名工人在Lennar Bridgeway home development的一栋在建房屋上进行维修。住宅建筑商Lennar将于今天收盘后公布第四季度收益。(贾斯汀·沙利文/盖蒂图片社摄)贾斯汀·沙利文来自盖蒂图片社</span></p></blockquote></p><p>Throughout most of the year, the housing market has remained hot. Similar to other industries, like electronics, housing has faced supply bottlenecks and labor shortages which have restricted supply in the face of rising demand. The Federal Housing Finance Agency reported that housing prices grew 18.5% through 2021 Q3 compared to a year ago, culminating in the largest annual increase in the agency’s House Price Index.</p><p><blockquote>在这一年的大部分时间里,住房市场一直保持着火热。与电子等其他行业类似,住房面临供应瓶颈和劳动力短缺,在需求不断增长的情况下限制了供应。联邦住房金融局报告称,截至2021年第三季度,房价同比增长18.5%,最终创下该机构房价指数的最大年度涨幅。</blockquote></p><p><img src=\"https://static.tigerbbs.com/125965aa9230614070fe2f36dbe141ba\" tg-width=\"819\" tg-height=\"688\" width=\"100%\" height=\"auto\"/></p><p><blockquote></blockquote></p><p>Tesla was Gerber’s last recommendation, and his number one pick for investors in 2022. He had some bold predictions for the EV maker in his interview with Yahoo Finance Live.</p><p><blockquote>特斯拉是格伯的最后推荐,也是他2022年投资者的首选。他在接受雅虎财经直播采访时对这家电动汽车制造商做出了一些大胆的预测。</blockquote></p><p>“I think over the next decade, Tesla will be the most consequential company in the history of business,” Gerber said. “I think in 12 months, we're going to see amazing breakthroughs in AI and technology. And what Elon has done yet, we don't know, you want to own stock in this future. So with robotics, AI, and the dominance in the EV and climate space, Tesla is the best stock of all time.”</p><p><blockquote>“我认为在未来十年,特斯拉将成为商业史上最重要的公司,”格伯说。“我认为在12个月内,我们将看到人工智能和技术方面的惊人突破。而Elon到目前为止做了什么,我们不知道,你想在未来拥有股票。因此,凭借机器人、人工智能和在电动汽车和气候领域的主导地位,特斯拉是有史以来最好的股票。”</blockquote></p><p>Tesla certainly rewarded bullish investors in 2021. This year, Tesla stock has gained 56%, more than double the S&P 500’s 27% rise.</p><p><blockquote>特斯拉无疑在2021年回报了看涨的投资者。今年,特斯拉股价已上涨56%,是标普500 27%涨幅的两倍多。</blockquote></p><p>Even so, challenges remain. The company recalled nearly half a million of its Model 3 and Model S over safety issues concerning the cars’ rear view cameras and trunk. Industry experts have raised concerns regarding the sustainability of Tesla’s high market share in the EV market, as well as the possible emergence of competitors.</p><p><blockquote>即便如此,挑战依然存在。由于后视摄像头和后备箱存在安全问题,该公司召回了近50万辆Model 3和Model S。行业专家对特斯拉在电动汽车市场的高市场份额的可持续性以及可能出现的竞争对手表示担忧。</blockquote></p><p>Gerber cautioned investors not to be too concerned about the recalls. Recalls are relatively normal for car companies, and Tesla’s main strengths lay outside of their automobile services, anyway, he added.</p><p><blockquote>格柏警告投资者不要过于担心召回事件。他补充说,召回对于汽车公司来说是相对正常的,无论如何,特斯拉的主要优势在于汽车服务之外。</blockquote></p><p></p><p>“Tesla is a better AI technology company than a car company, as we've all learned over the last 10 years,” he said. “They build cars, but they're basically building an iPhone on wheels. And so the entire infrastructure that they've been building around service, for example, has been a big challenge for them. They've innovated some amazing things like mobile service.”</p><p><blockquote>“正如我们在过去10年中都了解到的那样,特斯拉是一家比汽车公司更好的人工智能技术公司,”他说。“他们制造汽车,但他们基本上是在制造一部带轮子的iPhone。因此,例如,他们围绕服务构建的整个基础设施对他们来说是一个巨大的挑战。他们创新了一些令人惊叹的东西,比如移动服务。”</blockquote></p><p>Overall, stocks stayed flat on the final trading day of 2021, giving this year’s Santa Claus Rally a rather muted finish. The S&P 500 reached an intraday high Thursday but fell in the afternoon. This year, the index reached a record high every month, a feat achieved only once before, in 2014.</p><p><blockquote>总体而言,股市在2021年最后一个交易日持平,让今年的圣诞老人反弹收官相当平淡。标普500周四触及盘中高点,但午后下跌。今年,该指数每个月都创下历史新高,此前仅在2014年实现过一次。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://finance.yahoo.com/news/top-3-stocks-to-watch-in-2022-analyst-171050141.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEN":"莱纳建筑公司","BK4553":"喜马拉雅资本持仓","BK4527":"明星科技股","BAC":"美国银行","BK4099":"汽车制造商","TSLA":"特斯拉","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4150":"赌场与赌博","MGM":"美高梅","BK4504":"桥水持仓","BK4559":"巴菲特持仓","BK4088":"住宅建筑","BK4550":"红杉资本持仓","BK4548":"巴美列捷福持仓","BK4207":"综合性银行","BK4551":"寇图资本持仓","BK4561":"索罗斯持仓"},"source_url":"https://finance.yahoo.com/news/top-3-stocks-to-watch-in-2022-analyst-171050141.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2200443647","content_text":"Investors should keep an eye out for casino and real estate stocks next year, according to Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.MGM (MGM), Lennar (LEN), and Tesla (TSLA) were selected as the top three stocks poised to rise in 2022 in Gerber’s preview. He joined Yahoo Finance Live on Thursday to discuss which stocks should perform best next year.“MGM is a long-term holding of ours and we've been adding to it on the weakness because of Omicron,” Gerber said. “And we absolutely believe this is the endgame for Corona, this winter being sort of one of the tougher winters again. But as each winter rolls on, this will become much more normal and much less disruptive.”MGM Resorts International, a giant in the hospitality and entertainment industry, specializes in casinos, hotels, and resorts. As the global outlook continues to improve and the economy adjusts to the new realities concerning COVID, Gerber noted, the hospitality sector could stand to benefit greatly.The prospect of interest rate hikes in 2022 looms over the economic picture for next year and has dampened some analysts’ expectations for stock market growth. “The probability of a 10% correction in the near term or over the next 12 months is elevated,” Bank of America’s (BAC) U.S. stock and quantitative strategy chief Savita Subramanian told Bloomberg earlier this month.Gerber, who expressed doubt that all three Fed rate hikes would come in 2022, had a more optimistic disposition.“We actually don't think the Fed will actually hit their three rate hikes next year, we'll see,” he said. “But if it does happen, it won't be till the end of the year, and so housing is a supply and demand imbalance on a massive scale. And home builders like Lennar, especially Lennar, which is a really large, established home builder in multiple regions, are just benefiting from this enormous demand. So every house they're building, the profits just go up every month because prices keep going up.”Lennar, a Florida-based home construction company, has suffered recently from supply chain disruptions related to the pandemic. However, industry experts expect many of these challenges within the housing market to be overcome next year. Research and Markets reported that the U.S. construction industry is expected to grow by 3.7% in 2022.NEWARK, CALIFORNIA - DECEMBER 15: A worker makes repairs to a home under construction at the Lennar Bridgeway home development on December 15, 2021 in Newark, California. Homebuilder Lennar will report fourth quarter earnings today after the closing bell. (Photo by Justin Sullivan/Getty Images)Justin Sullivan via Getty ImagesThroughout most of the year, the housing market has remained hot. Similar to other industries, like electronics, housing has faced supply bottlenecks and labor shortages which have restricted supply in the face of rising demand. The Federal Housing Finance Agency reported that housing prices grew 18.5% through 2021 Q3 compared to a year ago, culminating in the largest annual increase in the agency’s House Price Index.Tesla was Gerber’s last recommendation, and his number one pick for investors in 2022. He had some bold predictions for the EV maker in his interview with Yahoo Finance Live.“I think over the next decade, Tesla will be the most consequential company in the history of business,” Gerber said. “I think in 12 months, we're going to see amazing breakthroughs in AI and technology. And what Elon has done yet, we don't know, you want to own stock in this future. So with robotics, AI, and the dominance in the EV and climate space, Tesla is the best stock of all time.”Tesla certainly rewarded bullish investors in 2021. This year, Tesla stock has gained 56%, more than double the S&P 500’s 27% rise.Even so, challenges remain. The company recalled nearly half a million of its Model 3 and Model S over safety issues concerning the cars’ rear view cameras and trunk. Industry experts have raised concerns regarding the sustainability of Tesla’s high market share in the EV market, as well as the possible emergence of competitors.Gerber cautioned investors not to be too concerned about the recalls. Recalls are relatively normal for car companies, and Tesla’s main strengths lay outside of their automobile services, anyway, he added.“Tesla is a better AI technology company than a car company, as we've all learned over the last 10 years,” he said. “They build cars, but they're basically building an iPhone on wheels. And so the entire infrastructure that they've been building around service, for example, has been a big challenge for them. They've innovated some amazing things like mobile service.”Overall, stocks stayed flat on the final trading day of 2021, giving this year’s Santa Claus Rally a rather muted finish. The S&P 500 reached an intraday high Thursday but fell in the afternoon. This year, the index reached a record high every month, a feat achieved only once before, in 2014.","news_type":1,"symbols_score_info":{"LEN":0.9,"BAC":1,"MGM":1,"TSLA":1}},"isVote":1,"tweetType":1,"viewCount":2764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692498776,"gmtCreate":1641131205131,"gmtModify":1641131205394,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692498776","repostId":"2195481004","repostType":4,"isVote":1,"tweetType":1,"viewCount":2318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692241705,"gmtCreate":1641007168499,"gmtModify":1641007303819,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Happy safe new year!","listText":"Happy safe new year!","text":"Happy safe new year!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692241705","repostId":"2195441245","repostType":4,"isVote":1,"tweetType":1,"viewCount":3142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692973590,"gmtCreate":1640835532645,"gmtModify":1640835590581,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087109479010510","idStr":"4087109479010510"},"themes":[],"htmlText":"Good luck!","listText":"Good luck!","text":"Good luck!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692973590","repostId":"1174778626","repostType":4,"repost":{"id":"1174778626","kind":"news","pubTimestamp":1640822866,"share":"https://www.laohu8.com/m/news/1174778626?lang=zh_CN&edition=full","pubTime":"2021-12-30 08:07","market":"sg","language":"en","title":"Singapore Stock Market May Fade On Thursday<blockquote>新加坡股市周四可能会褪色</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174778626","media":"RTTNews","summary":"The Singapore stock market has tracked higher in two straight sessions, gathering almost 35 points o","content":"<p><html><head></head><body>The Singapore stock market has tracked higher in two straight sessions, gathering almost 35 points or 1.1 percent along the way. The Straits Times Index now sits just beneath the 3,140-point plateau and it's expected to remain in that neighborhood again on Thursday.</p><p><blockquote><html><head></head><body>新加坡股市连续两个交易日走高,上涨近35点或1.1%。海峡时报指数目前略低于3,140点的高位,预计周四将再次保持在该附近。</body></html></blockquote></p><p>The global forecast for the Asian markets is murky following reports that the Omicron variant of the coronavirus has fueled a worldwide spike in the illness. The European and U.S. markets were mixed and little changed and the Asian markets figure to follow that lead.</p><p><blockquote>有报道称,冠状病毒的奥密克戎变种在全球范围内引发了该疾病的激增,对亚洲市场的全球预测并不明朗。欧洲和美国市场涨跌互现,变化不大,亚洲市场也将紧随其后。</blockquote></p><p>The STI finished modestly higher on Wednesday following gains from the financials, industrials, properties and plantations.</p><p><blockquote>继金融、工业、房地产和种植园上涨后,海指周三小幅收高。</blockquote></p><p>For the day, the index gained 9.61 points or 0.31 percent to finish at 3,138.02 after trading between 3,132.87 and 3,140.52. Volume was 868.1 million shares worth 450.1 million Singapore dollars. There were 274 gainers and 156 decliners.</p><p><blockquote>当天,该指数在3,132.87点至3,140.52点之间交易后,上涨9.61点或0.31%,收于3,138.02点。成交量为8.681亿股,价值4.501亿新元。上涨274家,下跌156家。</blockquote></p><p>Among the actives, Ascendas REIT jumped 1.02 percent, while CapitaLand Integrated Commercial Trust added 0.49 percent, City Developments gathered 0.74 percent, Dairy Farm International tumbled 1.72 percent, DBS Group rose 0.09 percent, Genting Singapore surged 1.29 percent, Keppel Corp gained 0.39 percent, Mapletree Logistics Trust spiked 1.07 percent, Oversea-Chinese Banking Corporation collected 0.18 percent, SATS fell 0.26 percent, Singapore Airlines perked 0.60 percent, Singapore Exchange dipped 0.21 percent, SingTel sank 0.85 percent, Thai Beverage and Yangzijiang Shipbuilding both climbed 0.76 percent, United Overseas Bank and Jardine Matheson both advanced 0.56 percent, Wilmar International soared 1.21 percent and Hongkong Land, Mapletree Commercial Trust, Singapore Press Holdings, Singapore Technologies Engineering, SembCorp Industries and Comfort DelGro were unchanged.</p><p><blockquote>活跃股中,腾飞房地产投资信托上涨1.02%,凯德综合商业信托上涨0.49%,City Developments上涨0.74%,Dairy Farm International下跌1.72%,星展集团上涨0.09%,云顶新加坡飙升1.29%,吉宝企业上涨0.39%,丰树物流信托飙升1.07%,华侨银行上涨0.18%,新翔集团下跌0.26%,新加坡航空上涨0.60%,新加坡交易所下跌0.21%,新加坡电信下跌0.85%,泰国饮料和扬子江造船均上涨0.76%,大华银行和怡和国际均上涨0.56%,丰益国际飙升1.21%,香港置地、丰树商业信托、新加坡报业控股、新加坡科技工程、胜科工业和舒适德尔高持平。</blockquote></p><p>The lead from Wall Street provides little clarity. All three of the major averages opened higher on Wednesday, and the Dow stayed that way throughout. The NASDAQ quickly turned lower and finished slightly under the line. The S&P 500 bounced back and forth and ended slightly in the green.</p><p><blockquote>华尔街的领先优势并没有提供多少清晰度。周三,三大股指均高开,道琼斯指数始终保持这种状态。纳斯达克迅速转低,收盘略低于底线。标普500来回反弹,略微以果岭结束。</blockquote></p><p>The Dow advanced 90.42 points or 0.25 percent to finish at 36,488.63, while the NASDAQ dipped 15.51 points or 0.10 percent to close at 15,766.22 and the S&P rose 6.71 points or 0.14 percent to end at 4,793.06.</p><p><blockquote>道琼斯指数上涨90.42点或0.25%,收于36,488.63点;纳斯达克下跌15.51点或0.10%,收于15,766.22点;标准普尔指数上涨6.71点或0.14%,收于4,793.06点。</blockquote></p><p>Traders seemed reluctant to continue making significant moves following recent strength in the markets, which has helped stocks recover from the sell-off seen in reaction to initial reports about the Omicron variant of the coronavirus.</p><p><blockquote>在近期市场走强后,交易员似乎不愿继续采取重大举措,这帮助股市从有关冠状病毒奥密克戎变种的初步报道引发的抛售中恢复过来。</blockquote></p><p>While Omicron has contributed to a surge in new coronavirus cases around the world, traders seem optimistic that the milder symptoms associated with the new strain will not lead to a significant economic slowdown.</p><p><blockquote>尽管奥密克戎导致全球新冠病毒病例激增,但交易员似乎乐观地认为,与新毒株相关的较轻症状不会导致经济大幅放缓。</blockquote></p><p>On the U.S. economic front, the National Association of Realtors noted an unexpected pullback in pending home sales in November.</p><p><blockquote>在美国经济方面,全国房地产经纪人协会指出,11月份待售房屋销售意外回落。</blockquote></p><p>Crude oil prices moved higher Wednesday, extending recent gains after the Energy Information Administration said U.S. crude oil inventories fell more than expected last week. Crude oil for February delivery climbed $0.58 or 0.8 percent to $76.56 a barrel.</p><p><blockquote>原油价格周三走高,延续了近期涨幅,此前美国能源情报署表示上周美国原油库存降幅超过预期。2月份交割的原油价格上涨0.58美元,或0.8%,至每桶76.56美元。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stock Market May Fade On Thursday<blockquote>新加坡股市周四可能会褪色</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stock Market May Fade On Thursday<blockquote>新加坡股市周四可能会褪色</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">RTTNews</strong><span class=\"h-time small\">2021-12-30 08:07</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>The Singapore stock market has tracked higher in two straight sessions, gathering almost 35 points or 1.1 percent along the way. The Straits Times Index now sits just beneath the 3,140-point plateau and it's expected to remain in that neighborhood again on Thursday.</p><p><blockquote><html><head></head><body>新加坡股市连续两个交易日走高,上涨近35点或1.1%。海峡时报指数目前略低于3,140点的高位,预计周四将再次保持在该附近。</body></html></blockquote></p><p>The global forecast for the Asian markets is murky following reports that the Omicron variant of the coronavirus has fueled a worldwide spike in the illness. The European and U.S. markets were mixed and little changed and the Asian markets figure to follow that lead.</p><p><blockquote>有报道称,冠状病毒的奥密克戎变种在全球范围内引发了该疾病的激增,对亚洲市场的全球预测并不明朗。欧洲和美国市场涨跌互现,变化不大,亚洲市场也将紧随其后。</blockquote></p><p>The STI finished modestly higher on Wednesday following gains from the financials, industrials, properties and plantations.</p><p><blockquote>继金融、工业、房地产和种植园上涨后,海指周三小幅收高。</blockquote></p><p>For the day, the index gained 9.61 points or 0.31 percent to finish at 3,138.02 after trading between 3,132.87 and 3,140.52. Volume was 868.1 million shares worth 450.1 million Singapore dollars. There were 274 gainers and 156 decliners.</p><p><blockquote>当天,该指数在3,132.87点至3,140.52点之间交易后,上涨9.61点或0.31%,收于3,138.02点。成交量为8.681亿股,价值4.501亿新元。上涨274家,下跌156家。</blockquote></p><p>Among the actives, Ascendas REIT jumped 1.02 percent, while CapitaLand Integrated Commercial Trust added 0.49 percent, City Developments gathered 0.74 percent, Dairy Farm International tumbled 1.72 percent, DBS Group rose 0.09 percent, Genting Singapore surged 1.29 percent, Keppel Corp gained 0.39 percent, Mapletree Logistics Trust spiked 1.07 percent, Oversea-Chinese Banking Corporation collected 0.18 percent, SATS fell 0.26 percent, Singapore Airlines perked 0.60 percent, Singapore Exchange dipped 0.21 percent, SingTel sank 0.85 percent, Thai Beverage and Yangzijiang Shipbuilding both climbed 0.76 percent, United Overseas Bank and Jardine Matheson both advanced 0.56 percent, Wilmar International soared 1.21 percent and Hongkong Land, Mapletree Commercial Trust, Singapore Press Holdings, Singapore Technologies Engineering, SembCorp Industries and Comfort DelGro were unchanged.</p><p><blockquote>活跃股中,腾飞房地产投资信托上涨1.02%,凯德综合商业信托上涨0.49%,City Developments上涨0.74%,Dairy Farm International下跌1.72%,星展集团上涨0.09%,云顶新加坡飙升1.29%,吉宝企业上涨0.39%,丰树物流信托飙升1.07%,华侨银行上涨0.18%,新翔集团下跌0.26%,新加坡航空上涨0.60%,新加坡交易所下跌0.21%,新加坡电信下跌0.85%,泰国饮料和扬子江造船均上涨0.76%,大华银行和怡和国际均上涨0.56%,丰益国际飙升1.21%,香港置地、丰树商业信托、新加坡报业控股、新加坡科技工程、胜科工业和舒适德尔高持平。</blockquote></p><p>The lead from Wall Street provides little clarity. All three of the major averages opened higher on Wednesday, and the Dow stayed that way throughout. The NASDAQ quickly turned lower and finished slightly under the line. The S&P 500 bounced back and forth and ended slightly in the green.</p><p><blockquote>华尔街的领先优势并没有提供多少清晰度。周三,三大股指均高开,道琼斯指数始终保持这种状态。纳斯达克迅速转低,收盘略低于底线。标普500来回反弹,略微以果岭结束。</blockquote></p><p>The Dow advanced 90.42 points or 0.25 percent to finish at 36,488.63, while the NASDAQ dipped 15.51 points or 0.10 percent to close at 15,766.22 and the S&P rose 6.71 points or 0.14 percent to end at 4,793.06.</p><p><blockquote>道琼斯指数上涨90.42点或0.25%,收于36,488.63点;纳斯达克下跌15.51点或0.10%,收于15,766.22点;标准普尔指数上涨6.71点或0.14%,收于4,793.06点。</blockquote></p><p>Traders seemed reluctant to continue making significant moves following recent strength in the markets, which has helped stocks recover from the sell-off seen in reaction to initial reports about the Omicron variant of the coronavirus.</p><p><blockquote>在近期市场走强后,交易员似乎不愿继续采取重大举措,这帮助股市从有关冠状病毒奥密克戎变种的初步报道引发的抛售中恢复过来。</blockquote></p><p>While Omicron has contributed to a surge in new coronavirus cases around the world, traders seem optimistic that the milder symptoms associated with the new strain will not lead to a significant economic slowdown.</p><p><blockquote>尽管奥密克戎导致全球新冠病毒病例激增,但交易员似乎乐观地认为,与新毒株相关的较轻症状不会导致经济大幅放缓。</blockquote></p><p>On the U.S. economic front, the National Association of Realtors noted an unexpected pullback in pending home sales in November.</p><p><blockquote>在美国经济方面,全国房地产经纪人协会指出,11月份待售房屋销售意外回落。</blockquote></p><p>Crude oil prices moved higher Wednesday, extending recent gains after the Energy Information Administration said U.S. crude oil inventories fell more than expected last week. Crude oil for February delivery climbed $0.58 or 0.8 percent to $76.56 a barrel.</p><p><blockquote>原油价格周三走高,延续了近期涨幅,此前美国能源情报署表示上周美国原油库存降幅超过预期。2月份交割的原油价格上涨0.58美元,或0.8%,至每桶76.56美元。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.rttnews.com/3251959/singapore-stock-market-may-fade-on-thursday.aspx?type=acom\">RTTNews</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3251959/singapore-stock-market-may-fade-on-thursday.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174778626","content_text":"The Singapore stock market has tracked higher in two straight sessions, gathering almost 35 points or 1.1 percent along the way. The Straits Times Index now sits just beneath the 3,140-point plateau and it's expected to remain in that neighborhood again on Thursday.The global forecast for the Asian markets is murky following reports that the Omicron variant of the coronavirus has fueled a worldwide spike in the illness. The European and U.S. markets were mixed and little changed and the Asian markets figure to follow that lead.The STI finished modestly higher on Wednesday following gains from the financials, industrials, properties and plantations.For the day, the index gained 9.61 points or 0.31 percent to finish at 3,138.02 after trading between 3,132.87 and 3,140.52. Volume was 868.1 million shares worth 450.1 million Singapore dollars. There were 274 gainers and 156 decliners.Among the actives, Ascendas REIT jumped 1.02 percent, while CapitaLand Integrated Commercial Trust added 0.49 percent, City Developments gathered 0.74 percent, Dairy Farm International tumbled 1.72 percent, DBS Group rose 0.09 percent, Genting Singapore surged 1.29 percent, Keppel Corp gained 0.39 percent, Mapletree Logistics Trust spiked 1.07 percent, Oversea-Chinese Banking Corporation collected 0.18 percent, SATS fell 0.26 percent, Singapore Airlines perked 0.60 percent, Singapore Exchange dipped 0.21 percent, SingTel sank 0.85 percent, Thai Beverage and Yangzijiang Shipbuilding both climbed 0.76 percent, United Overseas Bank and Jardine Matheson both advanced 0.56 percent, Wilmar International soared 1.21 percent and Hongkong Land, Mapletree Commercial Trust, Singapore Press Holdings, Singapore Technologies Engineering, SembCorp Industries and Comfort DelGro were unchanged.The lead from Wall Street provides little clarity. All three of the major averages opened higher on Wednesday, and the Dow stayed that way throughout. The NASDAQ quickly turned lower and finished slightly under the line. The S&P 500 bounced back and forth and ended slightly in the green.The Dow advanced 90.42 points or 0.25 percent to finish at 36,488.63, while the NASDAQ dipped 15.51 points or 0.10 percent to close at 15,766.22 and the S&P rose 6.71 points or 0.14 percent to end at 4,793.06.Traders seemed reluctant to continue making significant moves following recent strength in the markets, which has helped stocks recover from the sell-off seen in reaction to initial reports about the Omicron variant of the coronavirus.While Omicron has contributed to a surge in new coronavirus cases around the world, traders seem optimistic that the milder symptoms associated with the new strain will not lead to a significant economic slowdown.On the U.S. economic front, the National Association of Realtors noted an unexpected pullback in pending home sales in November.Crude oil prices moved higher Wednesday, extending recent gains after the Energy Information Administration said U.S. crude oil inventories fell more than expected last week. Crude oil for February delivery climbed $0.58 or 0.8 percent to $76.56 a barrel.","news_type":1,"symbols_score_info":{"STI.SI":0.9}},"isVote":1,"tweetType":1,"viewCount":2349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}